奥精医疗上修去年业绩：股份支付金额调整后归母净利润获改善，但仍亏1266万元

Core Viewpoint - Aojing Medical Technology Co., Ltd. has revised its 2024 performance forecast, indicating a decline in revenue and net profit compared to the previous year [1][2] Financial Performance Summary - The corrected total operating revenue for 2024 is 206.03 million yuan, a decrease of 9.03% year-on-year [1] - The net profit attributable to shareholders of the parent company is -12.66 million yuan, a decline of 123.35% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is -28.37 million yuan, a decrease of 210.11% year-on-year [1] - The corrected operating profit is -7.36 million yuan, an increase of 48.79% compared to the previous forecast [1] - The corrected total profit is -0.90 million yuan, an increase of 44.29% compared to the previous forecast [1] - The corrected basic earnings per share is -0.09 yuan, an increase of 30.76% compared to the previous forecast [1] Reasons for Correction - The correction is primarily due to adjustments in share-based payment amounts following the determination of the number of participants in the second phase of restricted stock [2] - The adjustments have led to increases in total profit, net profit attributable to shareholders, net profit after deducting non-recurring gains and losses, basic earnings per share, and other financial metrics [2] - The company has expressed apologies for any inconvenience caused to investors and emphasized the importance of careful judgment and communication with auditors in future financial reporting [2]